OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial


SUWON, Republic of Korea, Sept. 24, 2020 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to evaluate the efficacy of OLX10010 as an adjunct therapy to reduce the recurrence of hypertrophic scars after scar revision surgery.

Hypertrophic scars are the result of an overgrowth of collagen in the dermis (the skin’s next layer) that may cause functional impairment and cosmetic disfigurement. Hypertrophic scarring occurs in 40% to 70% of patients following surgery. Currently, there is no FDA-approved drugs and few treatments supported by well-designed prospective studies.

The purpose of this prospective, randomized, double-blind, intra-subject, placebo-controlled Phase 2a study is to determine the efficacy of OLX10010 in reducing recurrence of hypertrophic scars. The study will assess both the reduction and recurrence of…

Click here for the full story.

Asian Stocks Up, But Capped by Stimulus Measures Uncertainty By Investing.com

Previous article

Investor Baillie Gifford bets on China in a post-coronavirus world

Next article

You may also like

Leave a Reply

Notify of

More in Earnings